

# Azerbaijan

Population 2014

9.6 million

| Estimates of TB burden * 2014 | Number (thousands)  | Rate (per 100 000 population) |
|-------------------------------|---------------------|-------------------------------|
| Mortality (excludes HIV+TB)   | 0.041 (0.037–0.045) | 0.42 (0.38–0.47)              |
| Mortality (HIV+TB only)       | 0.028 (0.021–0.036) | 0.29 (0.21–0.38)              |
| Prevalence (includes HIV+TB)  | 9.8 (4.4–17)        | 102 (46–179)                  |
| Incidence (includes HIV+TB)   | 7.4 (6.5–8.3)       | 77 (68–86)                    |
| Incidence (HIV+TB only)       | 0.13 (0.11–0.15)    | 1.4 (1.2–1.6)                 |

|                               |            |
|-------------------------------|------------|
| Case detection, all forms (%) | 78 (70–89) |
|-------------------------------|------------|

| Estimates of MDR-TB burden * 2014              | New           | Retreatment     |
|--|---------------|-----------------|
| % of TB cases with MDR-TB                      | 13 (10–16)    | 28 (22–34)      |
| MDR-TB cases among notified pulmonary TB cases | 470 (370–580) | 830 (660–1 000) |

| TB case notifications 2014             | New ** | Relapse |
|--|--------|---------|
| Pulmonary, bacteriologically confirmed | 1 877  | 905     |
| Pulmonary, clinically diagnosed        | 1 678  | 359     |
| Extrapulmonary                         | 829    | 140     |

|  |              |
|--|--------------|
| <b>Total new and relapse</b>           | <b>5 788</b> |
| Previously treated, excluding relapses | 1 751        |
| <b>Total cases notified</b>            | <b>7 539</b> |

Among 4 389 new cases:  
179 (4%) cases aged under 15 years; male:female ratio: 2.8

| Reported cases of RR-/MDR-TB 2014        | New          | Retreatment  | Total ** |
|--|--------------|--------------|----------|
| Cases tested for RR-/MDR-TB              | 2 059 (110%) | 3 901 (124%) | 5 960    |
| Laboratory-confirmed RR-/MDR-TB cases    |              |              | 1 007    |
| Patients started on MDR-TB treatment *** |              |              | 814      |

| TB/HIV 2014   | Number | (%)  |
|---|--------|------|
| TB patients with known HIV status                                   | 7 004  | (93) |
| HIV-positive TB patients  | 148    | (2)  |
| HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) |        |      |
| HIV-positive TB patients on antiretroviral therapy (ART)            | 101    | (68) |
| HIV-positive people screened for TB                                 | 1 661  |      |
| HIV-positive people provided with IPT                               | 296    |      |

| Treatment success rate and cohort size                    | (%)  | Cohort |
|---|------|--------|
| New cases registered in 2013                              | (82) | 4 294  |
| Previously treated cases registered in 2013               | (73) | 2 652  |
| HIV-positive TB cases, all types, registered in 2013      |      |        |
| RR-/MDR-TB cases started on second-line treatment in 2012 | (60) | 373    |
| XDR-TB cases started on second-line treatment in 2012     | (36) | 33     |

| Laboratories 2014                                      |                 |
|--|-----------------|
| Smear (per 100 000 population)                         | 0.7             |
| Culture (per 5 million population)                     | 3.6             |
| Drug susceptibility testing (per 5 million population) | 1.6             |
| Sites performing Xpert MTB/RIF                         | 7               |
| Is second-line drug susceptibility testing available?  | Yes, in country |

| Financing TB control 2015                    |     |
|--|-----|
| National TB programme budget (US\$ millions) | 6.3 |
| % Funded domestically                        | 19% |
| % Funded internationally                     | 81% |
| % Unfunded                                   | 0%  |


\* Ranges represent uncertainty intervals

\*\* Includes cases with unknown previous TB treatment history

\*\*\* Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having RR-/MDR-TB


## Tuberculosis profile

(Rate per 100 000 population per year)




■ Mortality (excludes HIV+TB)

(Rate per 100 000 population)




■ Prevalence

(Rate per 100 000 population per year)




■ Notified (new and relapse) ■ Incidence  
■ Incidence (HIV+TB only)

(Number of patients)



■ HIV-positive TB patients  
■ on CPT ■ on ART

Treatment success rate (%)



■ New ■ Retreatment  
■ HIV-positive ■ RR-/MDR-TB ■ XDR-TB

Total budget (US\$ millions)



■ Funded domestically ■ Funded internationally  
■ Unfunded